The Cytel Blog: Perspectives on Enquiry & Evidence

  On August 29th 2018, the FDA announced (1) that it would be establishing a Complex Innovative Trial Design (CID)..

In a January 2017 paper (1), the FDA reviewed 22 case studies where promising Phase 2 trials did not result in..

 At the recent Biosimilars Summit in Philadelphia, Cytel's Pantelis Vlachos presented on statistical challenges and..

We continue our case study series with this example of a Phase 3 design that uses Bayesian decision making combined..

Adaptive sample size re-estimation designs are an important part of the statistician's toolkit. In this first in a..

A paper "Best practices case studies for 'less well-understood' Adaptive designs", has been published by the DIA..

Adaptive Designs in Practice: Interview with NIHR Research Fellow Munya Dimairo NIHR and University of Sheffield..

 'The aim of a discussion should not be victory but progress.' This principle, expressed by the French essayist Joseph..